Efficacy of Tulamycin - AVZ against mycoplasma pneumonia in pigs

Respiratory diseases of pigs cause great economic damage all over the world. Mycoplasma hyopneumoniae ( M. hyopneumoniae ) is actively involved in the development of respiratory diseases in pigs. It is quite difficult to isolate an animal from a pathogen, especially since the mechanism of the disease is very complex and not fully understood [4]. The clinical signs of the disease are more pronounced around the age of 18-20 weeks, which are characterized by a dry cough, sneezing, and developmental delay [5].Improving management, maintenance and biosecurity practices allows us to control this infection. But even the most careful control cannot protect the pig population from respiratory diseases [2].The use of antimicrobial drugs active against M. hyopneumoniae is an integral part of the occurrence of the disease.The purpose of our tests was to determine the effectiveness of the drug Brulamycin-AVZ in porcine mycoplasma pneumonia. The experiment was conducted on 75 large white breed pigs. Animals of 19 weeks of age, with a live body weight of ± 45 kg. Two groups of pigs with obvious clinical signs of the disease were formed.There were 25 animals in each group. The first group was experimental (sick animals), the second served as a control (sick animals) and the third control group (intact animals). Experimental group (sick animals) Tulamycin-AVZ was administered at a dose of 100 mg/ml once intramuscularly in the neck area at the rate of 1 ml per 40 kg of body weight (2.5 mg of tulatromycin per 1 kg of body weight). The second group (sick animals) and the third (intact animals) acted as controls and did not receive the drug.Based on the data obtained, it can be concluded that the use of Tulamycin-AVZ once intramuscularly in the neck area at a dose of 1 ml per 40 kg of animal body weight gave a positive result in the dynamics of mycoplasma pneumonia. All the animals that received the drug recovered. There were no clinical signs of the disease. The DNA of Mycoplasma microorganisms was not detected in the studied samples of nasopharyngeal flushes, and no enterococcal culture was isolated.

Authors

Institutions

Publication Details

Journal
Legal regulation in veterinary medicine
Published
2025-04-21
DOI
https://doi.org/10.52419/issn2782-6252.2025.1.91
Primary Topic
Microbial infections and disease research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy of Tulamycin - AVZ against mycoplasma pneumonia in pigs

А. Н. Токарев, С.В. Енгашев, O. A. Tokareva, E. S. Engasheva
Legal regulation in veterinary medicine
Microbial infections and disease research
article

Efficacy of Tulamycin - AVZ against mycoplasma pneumonia in pigs

А. Н. Токарев, С.В. Енгашев, O. A. Tokareva, E. S. Engasheva
article en

Abstract

Respiratory diseases of pigs cause great economic damage all over the world. Mycoplasma hyopneumoniae ( M. hyopneumoniae ) is actively involved in the development of respiratory diseases in pigs. It is quite difficult to isolate an animal from a pathogen, especially since the mechanism of the disease is very complex and not fully understood [4]. The clinical signs of the disease are more pronounced around the age of 18-20 weeks, which are characterized by a dry cough, sneezing, and developmental delay [5].Improving management, maintenance and biosecurity practices allows us to control this infection. But even the most careful control cannot protect the pig population from respiratory diseases [2].The use of antimicrobial drugs active against M. hyopneumoniae is an integral part of the occurrence of the disease.The purpose of our tests was to determine the effectiveness of the drug Brulamycin-AVZ in porcine mycoplasma pneumonia. The experiment was conducted on 75 large white breed pigs. Animals of 19 weeks of age, with a live body weight of ± 45 kg. Two groups of pigs with obvious clinical signs of the disease were formed.There were 25 animals in each group. The first group was experimental (sick animals), the second served as a control (sick animals) and the third control group (intact animals). Experimental group (sick animals) Tulamycin-AVZ was administered at a dose of 100 mg/ml once intramuscularly in the neck area at the rate of 1 ml per 40 kg of body weight (2.5 mg of tulatromycin per 1 kg of body weight). The second group (sick animals) and the third (intact animals) acted as controls and did not receive the drug.Based on the data obtained, it can be concluded that the use of Tulamycin-AVZ once intramuscularly in the neck area at a dose of 1 ml per 40 kg of animal body weight gave a positive result in the dynamics of mycoplasma pneumonia. All the animals that received the drug recovered. There were no clinical signs of the disease. The DNA of Mycoplasma microorganisms was not detected in the studied samples of nasopharyngeal flushes, and no enterococcal culture was isolated.

Legal regulation in veterinary medicine(1)
St Petersburg University (RU), University of Veterinary Medicine (HU), Moscow State Academy of Veterinary Medicine and Biotechnology named after Skryabin (RU), Saint Petersburg State University of Veterinary Medicine (RU), All-Russian Research Institute of Veterinary Sanitation, Hygiene and Ecology (RU)
Openalex Percentile: Top 92%
Microbial infections and disease research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.